Abstract
e15580 Background: In patients with mRCC receiving vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs), diarrhea can be problematic. All grade diarrhea and grade 3-4 diarrhea ...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
